HC Wainwright Decreases Earnings Estimates for Biohaven

Biohaven Ltd. (NYSE:BHVN) – Stock analysts at HC Wainwright decreased their FY2030 earnings per share estimates for shares of Biohaven in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $1.84 for the year, down from their prior forecast of $2.12. HC Wainwright currently has a “Neutral” rating and a $10.00 target price on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($3.11) per share.

Several other research firms also recently issued reports on BHVN. Morgan Stanley boosted their price objective on shares of Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Royal Bank Of Canada lifted their target price on shares of Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a research report on Friday, June 26th. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a report on Wednesday, May 27th. Finally, Needham & Company LLC set a $11.00 price objective on Biohaven in a research report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Biohaven Trading Down 4.0%

NYSE BHVN opened at $13.57 on Friday. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -2.92 and a beta of 1.26. The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. Biohaven has a one year low of $7.48 and a one year high of $18.57. The company’s 50 day moving average price is $14.54 and its 200 day moving average price is $11.73.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15).

Hedge Funds Weigh In On Biohaven

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in Biohaven by 49.4% in the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after purchasing an additional 37,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Biohaven by 32.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after buying an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Biohaven by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock worth $14,174,000 after buying an additional 41,040 shares during the last quarter. Intech Investment Management LLC raised its holdings in Biohaven by 80.3% in the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after acquiring an additional 27,433 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in Biohaven by 1,097.8% in the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock valued at $125,000 after acquiring an additional 8,102 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.